A phase I/II study of cisplatin and radiation in combination with sorafenib in cervical cancer: Evaluation of biomarkers.

@article{Townsley2011API,
  title={A phase I/II study of cisplatin and radiation in combination with sorafenib in cervical cancer: Evaluation of biomarkers.},
  author={Carol Townsley and Michael F. Milosevic and M. A. Haider and Helen J. Mackay and Ivan W T Yeung and Sophie Kim and Wilfred Levin and Lee A Manchul and Sutinder Bindra and Katrina Macalpine and Lisa M Tinker and Lisa Wang and Jose Bernarto Quintos and Anthony W. Fyles and Amit Manulal Oza},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={5037}
}
5037 Background: This is a single-arm, open-label, phase I/II trial in patients with early stage carcinoma of the cervix investigating the addition of sorafenib (S), a dual kinase inhibitor with anti-VEGF properties which may increase the affect of chemotherapy and radiation on tumor cells. METHODS All patients received conventional treatment with radiation and chemotherapy (RTCT) but a low risk/para-aortic group received S alone in escalating doses for 1 week prior to the start of (RTCT… CONTINUE READING